GlassScriptPhysician profile
Joseph Brian Prigg
NPI 1245233105
$2,359.12
in general payments reported to CMS, 2019-2025
26 companies · $61.58 in 2025
The $61.58 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $466 · 2022: $608 · 2023: $766 · 2024: $458 · 2025: $61.58.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,285.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,285.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $301.66 | 2021-2024 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $238.10 | 2021-2025 | Rybelsus, Ozempic |
| Glaxosmithkline, LLC. | $222.96 | 2021-2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $206.34 | 2022-2025 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $165.18 | 2021-2023 | Jardiance |
| Abbvie INC. | $156.73 | 2021-2023 | |
| Astrazeneca Pharmaceuticals LP | $155.32 | 2021-2025 | Breztri, Airsupra |
| Exact Sciences Corporation | $115.28 | 2023-2024 | Cologuard Collection Kit |
| Astellas Pharma US INC | $98.73 | 2023-2024 | Veozah, Myrbetriq |
| Takeda Pharmaceuticals U.S.A., INC. | $96.99 | 2021-2024 | Trintellix |
| Pfizer INC. | $94.71 | 2021-2024 | |
| Amgen INC. | $94.26 | 2021-2023 | Otezla, Repatha |
| Daiichi Sankyo INC. | $67.05 | 2021-2023 | Injectafer |
| Sumitomo Pharma America, INC. | $45.28 | 2024 | Gemtesa |
| Otsuka America Pharmaceutical, INC. | $41.50 | 2023 | Rexulti |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $32.61 | 2022-2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $31.69 | 2022 | |
| Lundbeck LLC | $29.05 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $28.15 | 2021-2022 | |
| Amarin Pharma, INC. | $22.35 | 2021 | |
| Dexcom, INC. | $21.77 | 2022 | |
| Alexion Pharmaceuticals, INC. | $21.32 | 2023 | Strensiq |
| Merck Sharp & Dohme LLC | $19.10 | 2022 | |
| Esperion Therapeutics, INC. | $18.84 | 2022 | |
| Horizon Therapeutics Plc | $17.15 | 2021 | |
| Bausch Health US, LLC | $17.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Prigg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.